Portal de Periódicos da CAPES

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

2022; Elsevier BV; Volume: 23; Issue: 3 Linguagem: Inglês

10.1016/s1470-2045(21)00758-0

1474-5488

Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert K. Hills, Zulian Liu, Hongchao Pan, Richárd Pető, David Dodwell, Paul McGale, Carolyn Taylor, Prudence A. Francis, Michael Gnant, Francesco Perrone, Meredith M. Regan, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Lucy Davies, Fran Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, R. Jakesz, Christian Fesl, Olivia Pagani, Richard D. Gelber, Michelino De Laurentiis, Sabino De Placido, Ciro Gallo, Kathy S. Albain, Stewart Anderson, R. Arriagada, John M.S. Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa A. Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Matthew P. Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Kathleen I. Pritchard, Vinod Raina, Daniel Rea, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španič, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Sandra M. Swain,

Advanced Breast Cancer Therapies

For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors are more effective than tamoxifen in postmenopausal women but are ineffective in premenopausal women when used without ovarian suppression. We aimed to investigate whether premenopausal women treated with ovarian suppression benefit from aromatase inhibitors.